Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Julie Eastland — FY2025 total compensation $1,300,731

Julie Eastland is President and Chief Executive Officer of Zentalis Pharmaceuticals, Inc. (ZNTL). The company reported total compensation of $1,300,731 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$700,000
Bonus$0
Stock awards$99,772
Option awards$56,975
Non-equity incentive plan$441,000
Pension and non-qualified deferred compensation$0
All other compensation$2,984
Total$1,300,731

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Zentalis Pharmaceuticals, Inc. filed April 30, 2026, accession 0001725160-26-000027.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025President and Chief Executive Officer$700,000$0$99,772$56,975$441,000$0$2,984$1,300,731
FY2024President and Chief Executive Officer$94,231$250,000$7,791,824$52,471$383$8,188,909

Totals as disclosed in each year's own compensation disclosure for Zentalis Pharmaceuticals, Inc..

04

The other named executive officers of Zentalis Pharmaceuticals, Inc.

Named executive officerRoleFY2025 total
Andrea PaulFormer Chief Legal Officer and Corporate Secretary$2,988,669
Julie Eastland this pagePresident and Chief Executive Officer$1,300,731
Mark LacknerFormer Chief Scientific Officer$1,229,349
Ingmar BrunsChief Medical Officer$869,843
James BucherChief Legal Officer and Corporate Secretary$659,973

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Zentalis Pharmaceuticals, Inc. compensation brief.

05

The company page

Julie Eastland's compensation sits inside Zentalis Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Zentalis Pharmaceuticals, Inc. (ZNTL) compensation brief